DP
RARE icon

Diadema Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Diadema Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-123,300
Closed -$3.71M – 183
2025
Q3 		$3.71M Hold
123,300
– – 0.95% 37
2025
Q2 		$4.48M Hold
123,300
– – 1.37% 25
2025
Q1 		$4.46M Buy
123,300
+17,800
+17% +$741K 1.16% 24
2024
Q4 		$4.44M Buy
+105,500
New +$5.23M 1.9% 13

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Diadema Partners's RARE Position: Q1 2026 in Review

Diadema Partners opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 35,144 shares worth $736K. The stake represents 0.13% of the portfolio and ranks #97 among its holdings. This is a return to the name: Diadema Partners previously reported a position in RARE as recently as Q3 2025.

Diadema Partners first reported a position in RARE in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.96M in Q2 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Diadema Partners held 35,144 shares of Ultragenyx Pharmaceutical worth $736K as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new Diadema Partners position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.13% of Diadema Partners's portfolio in Q1 2026, its #97 holding.
  • Diadema Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 3 quarters since.
  • Diadema Partners's Ultragenyx Pharmaceutical position peaked at $1.96M in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.